Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814609 | 1.00 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2USP30HDAC4 | |
| SCHEMBL13801629 | 0.94 | HDAC4 (0.44) | TAS1R3TAS1R1TAS1R2USP30HDAC4 | |
| SCHEMBL13814680 | 0.94 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2USP30HDAC4 | |
| SCHEMBL13814655 | 0.94 | HDAC4 (0.44) | TAS1R3TAS1R1TAS1R2USP30HDAC4 | |
| SCHEMBL13801627 | 0.94 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2USP30HDAC4 | |
| SCHEMBL13814608 | 0.90 | HSD11B1 (0.48) | TAS1R3TAS1R1TAS1R2USP30HDAC4 | |
| SCHEMBL13801630 | 0.90 | HSD11B1 (0.48) | TAS1R3TAS1R1TAS1R2USP30HDAC4 | |
| SCHEMBL13801639 | 0.88 | HDAC4 (0.48) | USP30HDAC4HDAC6MEN1KMT2A | |
| SCHEMBL13814615 | 0.88 | HDAC4 (0.48) | USP30HDAC4HDAC6MEN1KMT2A | |
| SCHEMBL13814634 | 0.88 | USP30 (0.46) | USP30HDAC4HDAC6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | TAS1R3 1426/4885TAS1R1 1216/4885TAS1R2 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.